Clinical trial NCT04242147: A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors
Official title: A Phase 1, Open-label, Multiple-ascending Dose Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Solid Tumor
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2020-01-27
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This is a Phase1, open-label, sequential dose-escalation and dose-expansion study of KD033 (SAR445710) in adult participants with advanced or metastatic solid tumors. The main purpose of this study is to test KD033 (SAR445710) at different dose levels to see if it is safe and well tolerated when given once every 2 weeks and when given weekly. Additional purposes of the study are to find out whether the study drug has anti-cancer effects and how the study drug is processed by the body.

Detailed description: The foreseen treatment duration is until disease progression, unacceptable toxicity, criterion for withdrawal or for a maximum of 2 years.

Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically confirmed/documented advanced and/or metastatic solid tumor with at least one tumor lesion of location accessible to biopsy per clinical judgement of treating physician.
* Participants must be willing to provide a tumor biopsy at the following time points: Pre-treatment and at Cycle 4, Day 1. All other study eligibility criteria must be met before any biopsy sample is obtained.
* Measurable disease at baseline per RECIST v1.1 guidelines.
* Life expectancy of at least 3 months.
* Eastern Cooperative Oncology Group Performance Status (ECOG PS) score ≤ 1.
* Adequate organ and bone marrow functions.
* All toxicities related to prior radiotherapy, chemotherapy, or surgical procedure must have recovered to baseline or Grade ≤ 1 based on NCI-CTCAE v5.0 except alopecia (any grade), Grade 2 peripheral neuropathy and adverse events that are clinically non-significant or stable on supportive care.
* All participants, male and female, who are not surgically sterilized or postmenopausal must agree to use 'highly effective methods of contraception' during the study and for at least 60 days after the last dose of KD033 (SAR445710).
* Women of childbearing potential must have a negative pregnancy test within 7 days prior to KD033 (SAR445710) treatment.
* Ability to understand the purpose of the study, provide signed and dated informed consent from the participant/legal representative prior to performing any protocol-related procedures and able to comply with the study procedures and any locally required authorization.

Exclusion Criteria:

* Use of immunotherapy, biological therapy, cytokine therapy \< 21 days prior to the first dose of study drug.
* Use of immunomodulating agents \< 21 days prior to the first dose of study drug.
* Use of chemotherapy and approved tyrosine kinase inhibitor (TKI) therapy \< 14 days prior to the first dose of study drug.
* Anti PD-L1 or anti PD-1 therapy \< 6 weeks prior to the first dose of study drug.
* Radiotherapy within 14 days before the start of trial treatment (prior diagnostic biopsy is permitted), with the exception of palliative radiation as described: patients assigned to radiotherapy require at least 1 additional lesion that can be safely irradiated while sparing the index lesion(s), and for which radiation at the limited, palliative doses contemplated would be considered medically appropriate; The lesion should be causing some signs or symptoms (e.g., tumor-related pain), for which radiation is indicated per the physician's standard clinical practice.
* Use of any investigational drug or have major surgery within 28 days before the start of trial treatment
* Ongoing or recent (within 2 years) evidence of significant autoimmune disease that required systemic immunosuppressive treatments.
* Systemic therapy with immunosuppressive agents including corticosteroids within 14 days before the start of trial treatment with the exception of corticosteroid replacement therapy for adrenal insufficiency
* Rapidly progressive disease which, in the opinion of Investigator, may predispose to inability to tolerate treatment or trial procedure.
* History or clinical evidence of central nervous system primary tumors or metastases including leptomeningeal metastases unless they have been previously treated, demonstrated no progression at least 1 months, are asymptomatic and have had no requirement for steroids or enzyme inducing anticonvulsants in the last 14 days before Screening - Participants with suspected brain metastases at Screening should undergo a CT/MRI of the brain prior to study entry.
* Receipt of any organ transplantation including hematopoietic cell transplantation.
* Has a paraneoplastic syndrome of autoimmune nature.
* History of interstitial lung disease or severe obstructive pulmonary disease.
* Clinically significant cardiovascular/cerebrovascular disease.
* QTc(F) interval \> 450 ms for men or \> 470 ms for women)
* Left ventricular ejection fraction (LVEF) \< 50% as measured by an echocardiogram (ECHO).
* Active infection requiring therapy.
* Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding.
* Pregnant or breast-feeding women
* Known severe hypersensitivity reactions to monoclonal antibodies, any history of or recent (within 6 months) of anaphylaxis
* Vaccine administration within 4 weeks of investigational drug administration.
* Vaccination with live vaccines while on trial is prohibited. Administration of inactivated vaccines like inactivated influenza vaccines is allowed. COVID-19 vaccines are approved to be administered prior to KD033 (SAR445710) administration and during the treatment phase, however, it is preferred to not vaccinate during the 28-day DLT period.

Note: Other protocol-defined exclusion criteria could apply.

Primary outcomes:
measure: Occurrence of Dose Limiting Toxicities (DLTs)
timeFrame: Up to 28 days
measure: Treatment Emergent Adverse Events (TEAEs) and Treatment-related AEs by Severity
timeFrame: Up to 30 days after last treatment
Secondary outcomes:
measure: Best Overall Response (BOR)
timeFrame: Through study completion, an expected average of 1 year
measure: Duration Of Response (DOR)
timeFrame: Through study completion, an expected average of 1 year
measure: Exploration of KD033 (SAR445710) Pharmacokinetic (PK) Profile - AUC
timeFrame: Through study completion, an expected average of 1 year
measure: Exploration of KD033 (SAR445710) Pharmacokinetic (PK) Profile - Cmax
timeFrame: Through study completion, an expected average of 1 year
measure: Exploration of Anti-KD033 (SAR445710) Antibodies
timeFrame: Through study completion, an expected average of 1 year
Other outcomes:
Locations:
city: Santa Monica
country: United States
facility: UCLA Hematology/Oncology, 2020 Santa Monica Boulevard, Suite 600 - Site 042
state: California
city: Tampa
country: United States
facility: Moffitt Cancer Center - Site 102
state: Florida
city: Buffalo
country: United States
facility: Roswell Park Cancer Institute - 665 Elm St - Site 062
state: New York
city: Philadelphia
country: United States
facility: Fox Chase Cancer Center - 333 Cottman Avenue - Site 141
state: Pennsylvania
city: Pittsburgh
country: United States
facility: University of Pittsburgh Medical Center - Hillman Cancer Center - 5150 Centre Avenue, Suite 301 - Site 132
state: Pennsylvania
Study officials:
References: